Baseline data doesn't seem compatable with BETonMACE. I looked up a number of relevant data points and how they increase / decrease risk of death (Hazard Ratio (HR)). Although I estimated the Hazard Ratio for Time to ACS, by comparing LIXA to EXAMINE. Mind you these are still all estimates and humans are non-linear systems so it's unclear how each directly impacts the other. Although I will say all of my data comes from diabetic patients with heart disease. In the end, I find that the total risk ratio of BETonMACE to EXAMINE is actually in BETonMACE's favor. But the point of this exercise was not to determine the exact number but estimate if the two trials had reasonably similar patients in quality of health. In this case the answer I find is yes. Examine can be used as a good proxy for BETonMACE's placebo.